Novo Nordisk is countering a surge of low-cost generics in the weight-loss drug market, particularly in India, by launching a higher-dose version of its Wegovy injection priced at $399 per month, undercutting Eli Lilly's products. This strategic move seeks to preserve its dominant market position in the face of declining market value and increased pressure from competitors like Lilly's new weight-loss pill Foundayo. With the market for GLP-1 therapies evolving rapidly due to patent expirations, Novo must balance aggressive pricing strategies with the need for growth in an increasingly competitive landscape.
“The flood of cheap copies of Novo Nordisk's Ozempic in India is already reshaping the country’s fast-growing obesity market.”
“Novo Nordisk will price its new high-dose Wegovy shot at $399 a month for cash-pay patients.”
“Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment.”
“A reminder that $NVO's Dividend Yield is +5% right now while sitting on its 200 Monthly MA.”
“$NVO could double from here and still be undervalued and still be under its 200 WMA. You don’t need a return to ATH’s to make strong gains here.”
“$NVO Wegovy injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU.”
“In the US, adult obesity — which had only gone up since Gallup first started measuring it in 2008 — fell by nearly 3 percent between 2022 and 2025 as GLP-1 use surged.”
“Also happy $NVO Dividend day for those who bought and holding one of the best undervalued positions in the market right now.”
“$NVO Undercuts $LLY With High-Dose Wegovy at $399 a Month. Wegovy HD will cost $50 less than Zepbound.”
“On April 7, Novo Nordisk A/S (NYSE:NVO) said Wegovy HD, a higher-dose 7.2 mg version of its weight-management drug Wegovy, is now available nationwide in the United States for adults with obesity.”
“Novo Nordisk used those results to position Wegovy HD as an expansion of the broader Wegovy franchise.”
